You just read:

Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

News provided by

Genomic Health, Inc.

04 Jun, 2019, 08:00 BST